| The Problem of TP53-Mutant MDS/AML |
|
Clinical Lymphoma , Myeloma & Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| New Approaches for Anemia in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Pitfalls in Assessing Response to Treatment in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Kidney involvement in myelodysplastic syndromes |
|
Clinical Kidney Journal |
Myelodysplastic Syndromes (MDS) |
| Silver lining: reduced relapse with chronic GVHD after transplant for MDS |
|
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Graft Versus Host Disease (GVHD), Myelodysplastic Syndromes (MDS) |
| Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes |
|
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Myelodysplastic Syndromes (MDS) |
| Considerations for Drug Development in Myelodysplastic Syndromes |
|
Clinical Cancer Research |
Myelodysplastic Syndromes (MDS) |
| Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
|
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
|
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
| The Genomics of Myelodysplastic Syndromes: Origins of Disease Evolution, Biological Pathways, and Prognostic Implications |
|
Cells |
Myelodysplastic Syndromes (MDS) |
